News
ZLDPY
7.75
NaN%
--
Weekly Report: what happened at ZLDPY last week (0908-0912)?
Weekly Report · 09/15/2025 12:35
Weekly Report: what happened at ZLDPY last week (0901-0905)?
Weekly Report · 09/08/2025 12:37
Weekly Report: what happened at ZLDPY last week (0825-0829)?
Weekly Report · 09/01/2025 12:29
Weekly Report: what happened at ZLDPY last week (0818-0822)?
Weekly Report · 08/25/2025 12:48
Weekly Report: what happened at ZLDPY last week (0811-0815)?
Weekly Report · 08/18/2025 12:34
Weekly Report: what happened at ZLDPY last week (0804-0808)?
Weekly Report · 08/11/2025 12:48
Weekly Report: what happened at ZLDPY last week (0728-0801)?
Weekly Report · 08/04/2025 12:50
Weekly Report: what happened at ZLDPY last week (0721-0725)?
Weekly Report · 07/28/2025 12:51
Weekly Report: what happened at ZLDPY last week (0714-0718)?
Weekly Report · 07/21/2025 12:35
Weekly Report: what happened at ZLDPY last week (0707-0711)?
Weekly Report · 07/14/2025 12:51
Weekly Report: what happened at ZLDPY last week (0630-0704)?
Weekly Report · 07/07/2025 12:36
Weekly Report: what happened at ZLDPY last week (0623-0627)?
Weekly Report · 06/30/2025 12:47
Weekly Report: what happened at ZLDPY last week (0616-0620)?
Weekly Report · 06/23/2025 12:35
Weekly Report: what happened at ZLDPY last week (0609-0613)?
Weekly Report · 06/16/2025 12:46
Weekly Report: what happened at ZLDPY last week (0602-0606)?
Weekly Report · 06/09/2025 12:48
Weekly Report: what happened at ZLDPY last week (0526-0530)?
Weekly Report · 06/02/2025 13:03
Weekly Report: what happened at ZLDPY last week (0519-0523)?
Weekly Report · 05/26/2025 13:01
More
Webull provides a variety of real-time ZLDPY stock news. You can receive the latest news about ZEALAND PHAR A through multiple platforms. This information may help you make smarter investment decisions.
About ZLDPY
Zealand Pharma A/S is a Denmark-based biotechnology company. The Company is focused on the discovery, design and development of peptide-based medicines for metabolic and gastrointestinal diseases and other rare disease areas with unmet medical needs. The Company's peptide-based product candidates includes clinical development, registration and, potentially, commercialization. Its pipeline includes three product candidates in clinical development: glepaglutide, which is being developed to treat short bowel syndrome, or SBS; dasiglucagon formulated for use in a dual-hormone artificial pancreas system for better diabetes management; and dasiglucagon for use in the treatment of congenital hyperinsulinism. The Company operates in Denmark and the USA and has a portfolio of medicines and product candidates, including collaborations with Boehringer Ingelheim.